| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Flavanomarein targets multiple signaling pathways involved in metabolism and inflammation. It functions as a Syk inhibitor, NF-κB p65 inhibitor, and TGF-β1/Smad signaling inhibitor. The compound enhances AKT phosphorylation, which is critical for cell survival and insulin signaling. It regulates the expression of PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD, modulating pathways related to apoptosis, inflammation, and metabolism. In HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs), flavanomarein demonstrates lipid-lowering effects by suppressing the protein expression of disulfide-isomerase A3 precursor and fatty acid synthase, thereby inhibiting FFA-induced lipogenesis.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that flavanomarein possesses potent antioxidative properties, including free radical scavenging activity and inhibition of lipid peroxidation. In human HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs), the compound exhibits significant lipid-lowering effects. Flavanomarein significantly reduces intracellular levels of reactive oxygen species and improves mitochondrial membrane potential and ATP levels, thus protecting mitochondrial function in FFA-treated HepG2 cells. The compound suppresses the elevation of triglyceride levels and inhibits lipid peroxidation following FFA treatment. It also markedly suppresses the protein expression of disulfide-isomerase A3 precursor and fatty acid synthase.
|
| ln Vivo |
In vivo studies have shown that snow chrysanthemum aqueous extracts containing flavanomarein significantly reduce serum lipid levels and oxidative stress in animal models. The compound demonstrates protective effects against diabetic nephropathy in experimental models. Flavanomarein has been shown to improve insulin sensitivity, reduce blood glucose levels, and protect against oxidative damage in vivo. Its antihypertensive and anti-hyperlipidemic activities have been confirmed in animal studies. The compound's ability to modulate lipid metabolism and reduce oxidative stress contributes to its therapeutic potential for managing metabolic disorders including diabetes, hypertension, and hyperlipidemia.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, flavanomarein can be evaluated using cell-free systems to assess its antioxidant and enzyme inhibitory activities. Free radical scavenging activity is typically measured using DPPH and ABTS assays, where the compound's ability to neutralize stable free radicals is quantified. Lipid peroxidation inhibition is assessed using thiobarbituric acid reactive substances (TBARS) assays. Enzyme inhibition studies can be performed to evaluate the compound's effects on Syk kinase, NF-κB p65, and TGF-β1/Smad signaling components using purified proteins and appropriate substrates. IC50 values for target inhibition are determined through dose-response curves. These cell-free assays help elucidate the primary molecular mechanisms underlying flavanomarein's antioxidant and anti-inflammatory activities.
|
| Cell Assay |
In vitro cellular assays for flavanomarein are commonly performed using human HepG2 hepatocellular carcinoma cells treated with free fatty acids (FFAs) to model metabolic dysfunction. Cells are cultured in standard media and exposed to FFAs to induce lipid accumulation and oxidative stress. Flavanomarein is then added at various concentrations (typically 1-100 μM) for 24-48 hours. Lipid levels are measured using oil red O staining and triglyceride quantification assays. Reactive oxygen species are detected using DCFH-DA fluorescent probes. Mitochondrial membrane potential is assessed using JC-1 staining, and ATP levels are measured using luminescence-based assays. Protein expression of FAS, PDIA3, and other targets is analyzed by Western blotting.
|
| Animal Protocol |
In vivo animal experiments with flavanomarein are typically conducted using rodent models of metabolic disease. For diabetic nephropathy studies, streptozotocin-induced diabetic rats or mice are administered flavanomarein orally at doses ranging from 10-100 mg/kg daily for several weeks. Blood glucose levels, serum lipid profiles, and markers of renal function are monitored throughout the study. Kidney tissues are harvested for histological examination, including assessment of glomerular damage and fibrosis. For antihypertensive studies, spontaneously hypertensive rats are used, and blood pressure is measured using tail-cuff or telemetry methods. Oxidative stress markers such as MDA and antioxidant enzyme activities are measured in serum and tissue samples.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of flavanomarein have been partially characterized. The compound's solubility in DMSO is 67.5 mg/mL (149.87 mM). For in vivo formulation, it can be prepared in 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% saline at 2 mg/mL (4.44 mM), or in 10% DMSO + 90% saline at 6.75 mg/mL (14.99 mM). The compound is stable as a powder at -20°C for 3 years and in solution at -80°C for 1 year. Flavanomarein has a relative density of 1.665 g/cm³. Detailed PK parameters such as oral bioavailability, half-life, Cmax, and AUC are not extensively documented in the available literature.
|
| Toxicity/Toxicokinetics |
The toxicological profile of flavanomarein is not extensively characterized in the literature. As a natural flavonoid compound derived from Coreopsis tinctoria, it is generally considered to have a favorable safety profile. However, comprehensive toxicity studies including acute, subchronic, and chronic toxicity assessments are limited. The compound's safety for human use has not been established, and it is strictly intended for research purposes only. Researchers should follow standard laboratory safety practices when handling flavanomarein. The compound's effects at high concentrations and potential interactions with other drugs or compounds have not been fully investigated. Further toxicological studies are needed to fully characterize its safety profile and therapeutic window.
|
| References |
|
| Additional Infomation |
It has been reported that European fir (Abies pindrow) contains flavonoid marin, and relevant data is available for reference.
Flavanomarein is a promising natural compound for research into metabolic disorders including diabetes, hypertension, and hyperlipidemia. Its protective effects against diabetic nephropathy make it particularly relevant for studying kidney complications of diabetes. The compound's antioxidant and anti-inflammatory properties provide opportunities for investigating oxidative stress-related diseases. Flavanomarein can be used as a tool to study the molecular mechanisms of lipid metabolism, insulin signaling, and mitochondrial function. It is also valuable for research on natural product chemistry and the development of plant-derived therapeutic agents. The compound's ability to modulate multiple signaling pathways makes it an interesting candidate for combination therapy studies. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.39278
|
| Exact Mass |
450.116
|
| CAS # |
577-38-8
|
| Related CAS # |
(2R)-Flavanomarein; 56389-87-8
|
| PubChem CID |
101781
|
| Appearance |
White to off-white solid
|
| Density |
1.665g/cm3
|
| Boiling Point |
818.2ºC at 760 mmHg
|
| Melting Point |
243-246ºC
|
| Flash Point |
288.9ºC
|
| Index of Refraction |
1.712
|
| LogP |
-0.3
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
662
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C1C(OC2=C(C1=O)C=CC(=C2O)OC3C(C(C(C(O3)CO)O)O)O)C4=CC(=C(C=C4)O)O
|
| InChi Key |
DGGOLFCPSUVVHX-RTHJTPBESA-N
|
| InChi Code |
InChI=1S/C21H22O11/c22-7-15-16(26)18(28)19(29)21(32-15)31-13-4-2-9-11(24)6-14(30-20(9)17(13)27)8-1-3-10(23)12(25)5-8/h1-5,14-16,18-19,21-23,25-29H,6-7H2/t14-,15+,16+,18-,19+,21+/m0/s1
|
| Chemical Name |
(2S)-2-(3,4-dihydroxyphenyl)-8-hydroxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~74.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
